Outlook Therapeutics Secures Nasdaq Compliance but Pursues Reverse Split Ahead of FDA Decision

Outlook Therapeutics stock doubles in 2026, but management seeks a reverse split up to 1:50 ahead of the critical FDA decision on Lytenava for wet AMD, with shareholder vote on July 16.

Outlook Therapeutics has clawed its way back above the $1 minimum bid price required for continued Nasdaq listing, yet management is pushing forward with a reverse stock split as an insurance policy. The biopharma group’s shares have more than doubled since the start of 2026, but the rally masks a precarious financial position and a pivotal few weeks ahead. On July 16, shareholders will vote on a capital restructuring that includes a reverse split of up to 1:50 and an expansion of authorised shares to 600 million. Just 13 days later, on July 29, the US Food and Drug Administration (FDA) is scheduled to deliver its verdict on the company’s lead drug, Lytenava (ONS-5010), for wet age-related macular degeneration.

The Nasdaq listing standard is no longer an immediate threat. At the end of June, Outlook’s stock closed above $1 for ten consecutive trading days, satisfying the exchange’s requirement for the time being. However, the board views the proposed reverse split as a prudent measure to buffer against future volatility and to attract institutional investors, many of whom have internal price minimums. The simultaneous plan to boost authorised capital to 600 million shares signals that the company remains hungry for funding. As of March 31, 2026, Outlook held just $7.7 million in cash and equivalents, a figure that underscores the urgency of both the FDA decision and the capital raise.

The FDA has classified its review of Lytenava as a Class 1 resubmission, meaning no new clinical trials are required. The agency is focused on finalising the drug’s labelling. If approved, Lytenava would become the first regulated bevacizumab-based ophthalmic formulation in the United States, offering an alternative to the unregulated compounded solutions commonly used off-label. The European commercialisation is already underway: Outlook reported net sales of $128,000 from launches in Germany, Austria and the UK during the first quarter. While modest, those revenues provide a template for a potential US rollout.

The stock market has reflected the binary nature of the coming weeks. Shares changed hands at $1.45 as of the latest close, down 14.5% over the trailing seven days but up 86% on a monthly basis and 119% year to date. That dramatic recovery comes from a 52-week low of $0.16 set on March 24, 2026 — a level that highlights just how far the equity has travelled. Even so, the current price remains more than half below the 2025 high of $2.97. The 14-day relative strength index of 59.6 points to neutral territory, while an annualised volatility reading above 230% underscores the potential for violent swings in either direction.

With the shareholder vote and the FDA decision falling within two weeks of each other, Outlook Therapeutics is effectively navigating two separate but intertwined inflection points. The reverse split and capital authorisation could dilute existing holders significantly, but a positive FDA verdict would open the door to the US market and the revenue stream the company desperately needs. The next few weeks will determine which scenario — or a combination of both — ultimately shapes the stock’s trajectory.